Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Palatin Technologies (PTN) Completed Last Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder

Source Link:: http://www.irdirect.net/pr/release/id/2030429

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

PTN

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Each North American (primarily U.S.) reconnect study is a multicenter (~80 sites), randomized, placebo controlled, parallel-group, eight month trial with an open-label extension phase. The clinical trials are designed to randomize approximately 1100 women (~550 each trial) to evaluate the efficacy and safety of subcutaneous bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD) as an on-demand, as-needed treatment.

http://www.palatin.c...

Additional Relevant Details . We now look forward to data verification and database lock, which we anticipate occurring in late September, with topline data announced shortly thereafter

http://www.irdirect....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Aug 04, 2016

Occurred Source:

http://www.irdirect.net/pr/release/id/2030429

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Top-line, Bremelanotide, Female Sexual Dysfunction, Fsd, Q3 2016